Oncology

Latest News

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com
RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

July 23rd 2025

G
In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds
January 4th 2020

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

Mary Caffrey
Testicular cancer is the most common cancer to be diagnosed in men as younger men—those younger than age 40—and it can be particularly aggressive. Advances in therapy have improved survival rates, but if young men have chemotherapy after surgery, they may live with side effects for decades.
What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer
January 2nd 2020

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

AJMC Staff
Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.
An Immune-Suppressing Target for Glioblastoma?
December 27th 2019

An Immune-Suppressing Target for Glioblastoma?

Mary Caffrey
A team at The University of Texas MD Anderson Cancer Center in Houston led by original pioneers in immuno-oncology have published a paper in Nature Medicine that discusses an immune-suppressing enzyme that was strongly present in glioblastoma but not in 5 other tumor types the team studied.
Site Logo
December 19th 2019

Improving Survival in Lung Cancer: Commitment of The Lung Ambition Alliance

Giorgio Scagliotti, MD, PhD
For more than 45 years, the International Association for the Study of Lung Cancer has been working tirelessly toward a world without lung and other thoracic cancers. To add strength to our efforts we recently joined with other leading organizations in the lung cancer space to create a powerful force for change: The Lung Ambition Alliance
Future of BCC and CSCC Therapy
December 19th 2019

Future of BCC and CSCC Therapy

Second-Line Systemic Treatment of BCC
December 19th 2019

Second-Line Systemic Treatment of BCC

Systemic Therapy in BCC
December 19th 2019

Systemic Therapy in BCC

Electing for Surgery in the Management of BCC
December 19th 2019

Electing for Surgery in the Management of BCC

Overview of Basal Cell Carcinoma
December 19th 2019

Overview of Basal Cell Carcinoma

Toxicity Profile and Pseudoprogression
December 19th 2019

Toxicity Profile and Pseudoprogression

PD-1 and Other Systemic Treatment Options for CSCC
December 19th 2019

PD-1 and Other Systemic Treatment Options for CSCC

Using Immunotherapy in CSCC
December 19th 2019

Using Immunotherapy in CSCC

Systemic Treatment of CSCC
December 19th 2019

Systemic Treatment of CSCC

Standard of Care for CSCC
December 19th 2019

Standard of Care for CSCC

Overview of Cutaneous Squamous Cell Carcinoma
December 19th 2019

Overview of Cutaneous Squamous Cell Carcinoma

Site Logo
December 18th 2019

Radiation Oncologist Discusses Concerns With Incoming CMS Payment Model

Allison Inserro
As CMS prepares to move forward with new models of value-based cancer care, a radiation oncologist, speaking at the Institute for Value-Based Medicine®, discussed her findings regarding whether accountable care models had an effect on cancer care spending.
Site Logo
December 18th 2019

Hope and Some Skepticism Whether Oncology Payment Models Will Work

Allison Inserro
Coverage from the Institute for Value-Based Medicine® session held in Nashville, Tennessee.
Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines
December 18th 2019

Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines

Maggie L. Shaw
In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment.
Government-Insured Patients With Breast Cancer Face a Higher Risk of Death
December 17th 2019

Government-Insured Patients With Breast Cancer Face a Higher Risk of Death

Gianna Melillo
Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.
Site Logo
December 17th 2019

From the Editor-in-Chief: Lead, Follow, or Get Out of the Way

Joseph Alvarnas, MD
Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.
Site Logo
December 16th 2019

Provider Perspective: Stephen M. Schleicher, MD, MBA, Addresses Accountability Versus Control in Oncology Care First

Mary Caffrey
An article Schleicher co-wrote in JAMA Oncology, which appeared the day before the announcement of Oncology Care First, offered insights into the need for changes to the original OCM.
Site Logo
December 16th 2019

Provider Perspective: Kashyap Patel, MD, Sees Collaboration Going Into Oncology Care First

Mary Caffrey
Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), said he’s optimistic about Oncology Care First.
Site Logo
December 16th 2019

Can Cancer Care Lead the Way Toward a Value-Based Future?

Keely Macmillan, MPH
A senior vice president of Archway Health discusses challenges and opportunities of the proposed Oncology Care First model.
Anthracycline, Radiation Treatment for Childhood Cancer Shown to Increase Risk of Adult Breast Cancer
December 12th 2019

Anthracycline, Radiation Treatment for Childhood Cancer Shown to Increase Risk of Adult Breast Cancer

Maggie L. Shaw
There was a 37% increase in childhood cancer survival between 1975 and 2010. With more children receiving chemotherapy and radiation to treat their diseases, leading to more survivors, awareness has grown of the belated effects of those treatments once patients reach adulthood.
Site Logo
December 11th 2019

Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations

Jakub P. Hlávka, PhD Pei-Jung Lin, PhD Peter J. Neumann, ScD
This review presents a set of evidence-based outcome measures for oncology alternative payment models, drawing on evidence from existing and proposed quality measures.
Supplemental MRI of Very Dense Breast Tissue Finds Early Cancers, at Higher Risk of False Positives
December 11th 2019

Supplemental MRI of Very Dense Breast Tissue Finds Early Cancers, at Higher Risk of False Positives

Gianna Melillo
A recent study published in The New England Journal of Medicine says that women with dense breast tissue who undergo supplemental magnetic resonance imaging (MRI) tests have lower rates of interval cancers than those who receive only mammography tests, although they also had higher rates of false positive tests.
Jennifer Atkins Describes Blue Cross Blue Shield's Commitment to Innovations in Oncology
December 8th 2019

Jennifer Atkins Describes Blue Cross Blue Shield's Commitment to Innovations in Oncology

Blue Cross Blue Shield is dedicated to maintaining local relationships to ensure they can provide the best care continuum to patients, said Jennifer Atkins, MBA, vice president of Network Solutions at Blue Cross Blue Shield.
NHS Staffing Shortages Behind Delays in Cancer Diagnoses for Patients in UK
December 7th 2019

NHS Staffing Shortages Behind Delays in Cancer Diagnoses for Patients in UK

Gianna Melillo
Patients waited about 2 months longer than necessary for a cancer diagnosis in the United Kingdom, according to a study published this week.
Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy
December 4th 2019

Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy

Maggie L. Shaw
Heart issues in patients with cancer and survivors can present themselves months or years after treatment.
Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News
December 1st 2019

Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
<1
...
212223242526272829
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo